Work

Markers of Initial and Long-Term Responses to Idecabtagene Vicleucel (Ide-Cel; bb2121) in the CRB-401 Study in Relapsed/Refractory Multiple Myeloma

Year: 2019

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2019-124998

Authors: Ethan G. Thompson, Yue Jiang, Timothy B. Campbell, Jaymes Fuller, Shari Kaiser, Afshin Mashadi-Hossein, Julie Rytlewski, Nathan Martin, Olivia Finney, Katja Kleinsteuber, Eric Alonzo, Chetanya Pandya, Amit Agarwal, Kristen Hege, Noopur S. Raje, Nikhil C. Munshi, Ronald J. Hause

Institutions: Celgene (United States), Bluebird Bio (United States), Massachusetts General Hospital, Dana-Farber Cancer Institute

Language: English

Topic: CAR-T cell therapy research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2988832519

Cites:

Cited by: 3

Related to: 10